8-K: Immunocore CFO Brian Di Donato to Resign at Year-End, Search for Successor Begins

Immunocore's Chief Financial Officer, Brian Di Donato, will resign at the end of 2024 to become CEO of a private biotech company, prompting a search for his replacement.

Summary

• Immunocore Holdings plc announced that its Chief Financial Officer and Head of Strategy, Brian Di Donato, will be resigning effective December 31, 2024.
• Mr. Di Donato is leaving to take on the role of Chief Executive Officer at a private, early-stage biotech company in San Diego, California.
• His resignation is not due to any disagreements with the company regarding financial statements, internal controls, or operations.
• Immunocore has initiated a formal search for a new CFO to ensure a smooth transition.
• Mr. Di Donato will remain in his current role until the end of the year to assist with the transition.

Sentiment

Score: 6

Explanation: The news of the CFO's departure is a moderate negative, but the company is handling the transition well and has a strong pipeline. The CFO is leaving for a better opportunity, which is not a negative reflection on the company.

Positives

• Mr. Di Donato will remain in his position until the end of 2024 to ensure a smooth transition.
• The company has already begun a formal search for a replacement.
• The company acknowledges Mr. Di Donato's contributions, including the successful IPO and building a strong finance department.
• Immunocore has a deep pipeline with nine active clinical and pre-clinical programs.
• The company has successfully launched KIMMTRAK, the world's first TCR therapy.

Negatives

• The departure of a key executive like the CFO could create some uncertainty.
• The company will need to find a suitable replacement for the CFO, which may take time.

Risks

• The company faces risks related to worsening macroeconomic conditions, which could impact its business and financial position.
• There are risks associated with obtaining clinical and commercial supplies of products.
• The company faces risks related to regulatory approvals, clinical trial delays, and competition.
• The company's ability to obtain additional funding is subject to market conditions and other factors.
• There are risks related to intellectual property protection and the success of collaborations.

Future Outlook

Immunocore plans to continue developing its clinical and research portfolio, including planned data readouts of three Phase 3 clinical trials and expansion into autoimmune diseases. The company is also searching for a new CFO.

Management Comments

• Bahija Jallal, Chief Executive Officer at Immunocore, stated that Brian has been an invaluable member of the team and his leadership was instrumental in the success of their IPO.
• Brian Di Donato said he is proud of what they have accomplished at Immunocore and honored to have worked with such a talented team.

Industry Context

The departure of a CFO to become CEO of another biotech company is not uncommon in the industry, reflecting the high demand for experienced leaders in the sector. Immunocore's focus on TCR therapies and its commercial-stage status position it as a significant player in the biotechnology space.

Comparison to Industry Standards

• The transition of a CFO to a CEO role in another biotech company is a common career progression within the industry, reflecting the value placed on financial and strategic leadership experience.
• Immunocore's focus on TCR therapies is a specialized area within biotechnology, with companies like Adaptimmune and TCR2 Therapeutics also developing similar technologies.
• The company's successful launch of KIMMTRAK places it among the few companies with approved TCR-based therapies, setting a benchmark for others in the field.

Management Changes

Stakeholder Impact

• Shareholders may experience some uncertainty due to the departure of a key executive.
• Employees may be affected by the change in leadership in the finance department.
• Customers and partners may not be significantly impacted by this change.

Next Steps

• Immunocore will conduct a formal search for a new Chief Financial Officer.
• The company will continue to develop its clinical and research portfolio.
• Immunocore will proceed with planned data readouts of three Phase 3 clinical trials.
• The company will continue its expansion into autoimmune diseases.

Key Dates

Keywords

CFO, Chief Financial Officer, Immunocore, resignation, biotech, executive, finance, KIMMTRAK, clinical trials, ImmTAX, TCR therapy